The ADA recommends that patients with T2DM, particularly those with established atherosclerotic cardiovascular disease (ASCVD) or a high cardiovascular risk, should utilize GLP-1-RAs as the first-line therapy in conjunction with metformin. Here, GLP1R is linked to atherosclerosis.